Biotech Values

[EnergyFundies]

Here is where I get my estimate from (11/14 Stifel conference q&a)

Brian:
Yeah, it's really an enrollment timing issue. This study, like I mentioned a minute ago, with the multiple-ascending dose that was subcu, each cohort needs to be completed before the next one is started. So it's a 28-day treatment window, and then there's probably around two to three weeks of data analysis. You got to clean up the
database. There's PK draws after that, 28 days as well. And then the dose level review team meets, discusses the data, and makes a recommendation. So, in a perfect world, all of the subjects show up on day 1, and they all complete on day 28. And then in three weeks you can start the next cohort.

In reality, what has happened with multiple cohorts now is you get maybe two people showing up on day one; two
people showing up on day 15; two people showing up on day 20. And so, the last couple of people have to get through the 28-day window and that extra three weeks or so before a recommendation is rendered. So, it just – you could – you push out what should be a six or seven week window to, you know, potentially double that in
some situations.